| Product Code: ETC10223244 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
Despite a significant decline in growth rate in 2024, the Netherlands continues to be a key importer of prostate-specific antigen blood-based biomarkers. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, with top exporting countries being Belgium, Hungary, USA, Japan, and Sweden. With a steady compound annual growth rate (CAGR) of 3.85% from 2020 to 2024, the Netherlands remains a lucrative market for these biomarker imports, showcasing consistent demand and potential for further expansion in the future.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market - Industry Life Cycle |
3.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market - Porter's Five Forces |
3.5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.6 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume Share, By Test Sensitivity, 2021 & 2031F |
3.8 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume Share, By End Use, 2021 & 2031F |
3.9 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume Share, By Distribution, 2021 & 2031F |
4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of prostate cancer in the Netherlands |
4.2.2 Growing awareness about the importance of early detection and screening for prostate cancer |
4.3 Market Restraints |
4.3.1 Regulatory challenges in the approval and commercialization of new biomarker tests |
4.3.2 Limited reimbursement policies for prostate-specific antigen testing in the Netherlands |
5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Trends |
6 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By Types |
6.1 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Application, 2021 - 2031F |
6.1.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Diagnostic Testing, 2021 - 2031F |
6.1.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Screening, 2021 - 2031F |
6.1.5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Prognostic Testing, 2021 - 2031F |
6.1.6 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Monitoring, 2021 - 2031F |
6.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By Type |
6.2.1 Overview and Analysis |
6.2.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Serum PSA, 2021 - 2031F |
6.2.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Free PSA, 2021 - 2031F |
6.2.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Total PSA, 2021 - 2031F |
6.2.5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Complex PSA, 2021 - 2031F |
6.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By Test Sensitivity |
6.3.1 Overview and Analysis |
6.3.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By High Sensitivity, 2021 - 2031F |
6.3.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Low Sensitivity, 2021 - 2031F |
6.3.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Specificity, 2021 - 2031F |
6.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By End Use |
6.4.1 Overview and Analysis |
6.4.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.4.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
6.5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market, By Distribution |
6.5.1 Overview and Analysis |
6.5.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Direct-to-Consumer, 2021 - 2031F |
6.5.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Pharmacies, 2021 - 2031F |
6.5.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenues & Volume, By Hospitals, 2021 - 2031F |
7 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Import-Export Trade Statistics |
7.1 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Export to Major Countries |
7.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Imports from Major Countries |
8 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Key Performance Indicators |
8.1 Adoption rate of prostate-specific antigen blood-based biomarker testing among healthcare providers in the Netherlands |
8.2 Number of research studies and publications supporting the efficacy of prostate-specific antigen testing |
8.3 Patient adherence and compliance rates with recommended prostate cancer screening guidelines |
8.4 Rate of technological advancements in prostate-specific antigen testing methodologies |
9 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market - Opportunity Assessment |
9.1 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Opportunity Assessment, By Application, 2021 & 2031F |
9.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Opportunity Assessment, By Type, 2021 & 2031F |
9.3 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Opportunity Assessment, By Test Sensitivity, 2021 & 2031F |
9.4 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Opportunity Assessment, By End Use, 2021 & 2031F |
9.5 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Opportunity Assessment, By Distribution, 2021 & 2031F |
10 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market - Competitive Landscape |
10.1 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Revenue Share, By Companies, 2024 |
10.2 Netherlands Prostate-Specific Antigen Blood-Based Biomarker Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here